Published in J Exp Med on April 01, 1967
Secretory products of macrophages. J Clin Invest (1987) 10.33
Tumour-necrosis factor from the rabbit. II. Production by monocytes. Br J Cancer (1978) 2.48
Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med (1991) 2.16
Secretory function of mononuclear phagocytes: a review. Am J Pathol (1976) 2.12
Inducers of interferon and host resistance, V. In vitro studies. Proc Natl Acad Sci U S A (1968) 1.68
Action of interferon: kinetics and differential effects on viral functions. J Virol (1970) 1.63
A human interferon that crosses the species line. Proc Natl Acad Sci U S A (1968) 1.52
Cellular origin of interferon induced by bacterial lipopolysaccharide. Infect Immun (1977) 1.44
Proliferation and colony-forming ability of peritoneal exudate cells in liquid culture. J Exp Med (1975) 1.38
Interferon production in mixed lymphocyte cell cultures. Infect Immun (1971) 1.34
Tumour-necrosis factor from the rabbit. III. Relationship to interferons. Br J Cancer (1979) 1.23
In vitro interaction of mouse hepatitis virus and macrophages from genetically resistant mice. II. Biological characterization of a variant virus MHV (C3H) isolated from stocks of MHV(PRI). J Exp Med (1970) 1.21
The distribution of immunoreactive interferon-alpha in normal human tissues. Immunology (1989) 1.18
Rabbit macrophage interferons. II. Some physicochemical properties and estimations of molecular weights. J Exp Med (1967) 1.16
Spontaneous production of human interferon. Proc Natl Acad Sci U S A (1980) 1.14
The role of individual spleen cells in the interferon response of the intact mouse. Proc Natl Acad Sci U S A (1969) 1.05
Comparative production of interferon by explanted lymphoreticular tissue and alveolar macrophages from rabbits and humans. Infect Immun (1976) 0.97
Roles of interferon produced in physiological conditions. A speculative review. Immunology (1988) 0.91
Interferon production by leukocytes infiltrating the lungs of mice during primary influenza virus infection. Infect Immun (1982) 0.89
Purified rabbit interferon: attempts to demonstrate interferon-specific 3H-protein. J Virol (1970) 0.89
Resistance to Babesia spp. and Plasmodium sp. in mice pretreated with an extract of Coxiella burnetii. Infect Immun (1979) 0.87
Interferon production by macrophages from adult and newborn rabbits bearing fibroma virus-induced tumors. Infect Immun (1974) 0.86
Thymus-derived lymphocytes control the expression of immunogenic properties of peritoneal macrophages. Proc Natl Acad Sci U S A (1979) 0.83
Natural interferon-producing cells in mice. Infect Immun (1981) 0.83
Host DNA synthesis-suppressing factor in culture fluid of tissue cultures infected with measles virus. J Virol (1974) 0.80
Interferon--1968. How much do we understand? Calif Med (1968) 0.77
Variation of interferon production during the cell cycle. Appl Microbiol (1970) 0.76
Inhibition of herpes simplex virus strains isolated from herpetic keratitis by polyinosinic acid-polycytidylic acid. Antimicrob Agents Chemother (1977) 0.75
THE DIFFERENTIATION OF MONONUCLEAR PHAGOCYTES. MORPHOLOGY, CYTOCHEMISTRY, AND BIOCHEMISTRY. J Exp Med (1965) 21.86
Studies on pulmonary alveolar macrophages from the normal rabbit: a technique to procure them in a high state of purity. J Immunol (1961) 9.52
MOUSE MACROPHAGES AS HOST CELLS FOR THE MOUSE HEPATITIS VIRUS AND THE GENETIC BASIS OF THEIR SUSCEPTIBILITY. Proc Natl Acad Sci U S A (1960) 6.27
BIOLOGIC PROPERTIES OF TWO PLAQUE VARIANTS OF VESICULAR STOMATITIS VIRUS (INDIANA SEROTYPE). J Immunol (1963) 5.30
ASPECTS OF THE PATHOGENESIS OF VIRUS DISEASES. Bacteriol Rev (1964) 5.03
CIRCULATING INTERFERON IN MICE AFTER INTRAVENOUS INJECTION OF VIRUS. Science (1963) 3.48
Interferon appearance stimulated by endotoxin, bacteria, or viruses in mice pre-treated with Escherichia coli endotoxin or infected with Mycobacterium tuberculosis. Nature (1965) 3.34
PATTERNS OF INTERFERON APPEARANCE IN MICE INFECTED WITH BACTERIA OR BACTERIAL ENDOTOXIN. Nature (1964) 3.32
Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin. Science (1965) 3.06
ENHANCEMENT OF CHIKUNGUNYA VIRUS REPLICATION AND INHIBITION OF INTERFERON PRODUCTION BY ACTINOMYCIN D. Virology (1963) 2.85
Leukocytes and interferon in the host response to viral infections. II. Enhanced interferon response of leukocytes from immune animals. J Bacteriol (1966) 2.78
The origin and turnover of mononuclear cells in peritoneal exudates in rats. J Exp Med (1966) 2.66
Production of interferon by suspensions of human leucocytes. Proc Soc Exp Biol Med (1961) 2.59
Influence of inhibitors of protein synthesis on interferon formation in mice. Virology (1965) 2.49
Studies on the pathogenesis of fever. XI. Quantitative features of the febrile response to leucocytic pyrogen. J Exp Med (1963) 2.42
Comparison of interferon production in mice by bacterial endotoxin and statolon. Virology (1966) 1.88
Interferon activity associated with high molecular weight proteins in the circulation of mice injected with endotoxin or bacteria. Virology (1965) 1.85
INHIBITION OF INTERFERON BIOSYNTHESIS BY ACTINOMYCIN D. Nature (1964) 1.73
PRODUCTION OF INTERFERON BY HUMAN MONONUCLEAR LEUCOCYTES. Proc Soc Exp Biol Med (1965) 1.65
EFFECT OF ACTINOMYCIN D ON VIRUS AND ENDOTOXIN-INDUCED INTERFERONLIKE INHIBITORS IN RABBITS. Proc Natl Acad Sci U S A (1965) 1.56
Interferon production by mouse leukocytes in vitro and in vivo. J Exp Med (1963) 1.55
INTERFERON. A REVIEW AND ANALYSIS OF RECENT OBSERVATIONS. Am J Med (1965) 1.54
Effect of interferon treatment on interferon production. J Immunol (1966) 1.49
Virus replication and high-titered interferon production in human leukocyte cultures inoculated with Newcastle disease virus. J Bacteriol (1966) 1.47
LEUKOCYTES AND INTERFERON IN THE HOST RESPONSE TO VIRAL INFECTIONS. I. MOUSE LEUKOCYTES AND LEUKOCYTE-PRODUCED INTERFERON IN VACCINIA VIRUS INFECTION IN VITRO. J Exp Med (1965) 1.46
Reversible inhibition of interferon synthesis by puromycin: evidence for an interferon-specific messenger RNA. Proc Natl Acad Sci U S A (1965) 1.44
Tolerance to the induction of interferons by endotoxin and virus: role of a humoral factor. Proc Soc Exp Biol Med (1965) 1.38
Production of interferon by alveolar macrophages. J Bacteriol (1966) 1.20
Rabbit macrophage interferons. II. Some physicochemical properties and estimations of molecular weights. J Exp Med (1967) 1.16
Role of the spleen in interferon production in mice. Proc Soc Exp Biol Med (1966) 1.11
Some aspects of the interferon production in vivo. Life Sci (1966) 1.02
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Comparative sedimentation coefficients of RNA extracted from plaque-forming and defective particles of vesicular stomatitis virus. J Mol Biol (1966) 6.61
Defective T particles of vesicular stomatitis virus. I. Preparation, morphology, and some biologic properties. Virology (1966) 6.37
Dissociation and reconstitution of the transcriptase and template activities of vesicular stomatitis B and T virions. J Virol (1972) 5.93
Classification of rhabdovirus proteins: a proposal. J Virol (1972) 5.54
Proteins of vesicular stomatitis virus: kinetics and cellular sites of synthesis. J Virol (1970) 4.85
Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75
Structural proteins of vesicular stomatitis viruses. J Virol (1969) 4.70
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Protein composition of the structural components of vesicular stomatitis virus. J Virol (1969) 4.54
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40
The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody. J Virol (1972) 4.04
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66
Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus. J Virol (1979) 3.54
Defective T particles of vesicular stomatitis virus. II. Biologic role in homologous interference. Virology (1966) 3.49
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
L protein requirement for in vitro RNA synthesis by vesicular stomatitis virus. J Virol (1973) 3.26
Lipid composition of purified vesicular stomatitis viruses. J Virol (1971) 3.25
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Telling the truth about terminal cancer. JAMA (1998) 3.07
Spatial relationships of the proteins of vesicular stomatitis virus: induction of reversible oligomers by cleavable protein cross-linkers and oxidation. J Virol (1977) 2.77
Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49
Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47
Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation (2001) 2.46
Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol (1992) 2.42
Carbohydrate composition of vesicular stomatitis virus. J Virol (1971) 2.40
Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol (1993) 2.39
A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38
Cytoplasmic compartmentalization of the protein and ribonucleic acid species of vesicular stomatitis virus. J Virol (1972) 2.37
Inhibition of cellular RNA synthesis by nonreplicating vesicular stomatitis virus. Proc Natl Acad Sci U S A (1965) 2.37
Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30
Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol (1995) 2.23
Protein kinase and phosphoproteins of vesicular stomatitis virus. J Virol (1974) 2.11
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07
Temperature-sensitive mutants of vesicular stomatitis virus: synthesis of virus-specific proteins. J Virol (1971) 2.05
Viral liposomes released from insect cells infected with recombinant baculovirus expressing the matrix protein of vesicular stomatitis virus. J Virol (1993) 2.02
Encephalopathy and fatty degeneratiof on the viscera in northeastern Thailand. Clinical syndrome and epidemiology. Pediatrics (1971) 2.00
Functional and antigenic domains of the matrix (M1) protein of influenza A virus. J Virol (1987) 1.98
The role of autolysins during vegetative growth of Bacillus subtilis 168. Microbiology (1998) 1.97
Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol (1989) 1.92
Localization of membrane-associated proteins in vesicular stomatitis virus by use of hydrophobic membrane probes and cross-linking reagents. J Virol (1980) 1.89
Association of vesicular stomatitis virus glycoprotein with virion membrane: characterization of the lipophilic tail fragment. J Virol (1975) 1.88
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res (2000) 1.86
Ribonucleic acid species of intracellular nucleocapsids and released virions of vesicular stomatitis virus. J Virol (1972) 1.86
Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80
Mapping regions of the matrix protein of vesicular stomatitis virus which bind to ribonucleocapsids, liposomes, and monoclonal antibodies. J Virol (1986) 1.78
Restitution of infectivity to spikeless vesicular stomatitis virus by solubilized viral components. J Virol (1975) 1.77
Physical and biological properties of dengue-2 virus and associated antigens. J Virol (1970) 1.75
Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J Virol (1989) 1.73
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2000) 1.71
Measuring standards of care for early breast cancer in an insured population. J Clin Oncol (1997) 1.71
Role of matrix protein in assembling the membrane of vesicular stomatitis virus: reconstitution of matrix protein with negatively charged phospholipid vesicles. Biochemistry (1981) 1.71
Inhibition of RNA and interferon synthesis in Krebs-2 cells infected with vesicular stomatitis virus. Virology (1966) 1.67
Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med (1991) 1.67
Regulation of viral transcription by the matrix protein of vesicular stomatitis virus probed by monoclonal antibodies and temperature-sensitive mutants. J Virol (1985) 1.66
Sialoglycoprotein of vesicular stomatitis virus: role of the neuraminic acid in infection. J Virol (1974) 1.63
Action of interferon: kinetics and differential effects on viral functions. J Virol (1970) 1.63
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol (2005) 1.62
Pulmonary function in firefighters: acute changes in ventilatory capacity and their correlates. Br J Ind Med (1979) 1.61
The plus-strand leader RNA of VSV inhibits DNA-dependent transcription of adenovirus and SV40 genes in a soluble whole-cell extract. Cell (1982) 1.61
Glycoprotein biosynthesis. Incorporation of glycosyl groups into endogenous acceptors in a Golgi apparatus-rich fraction of liver. J Biol Chem (1971) 1.60
Location of the transcription defect in group I temperature-sensitive mutants of vesicular stomatitis virus. J Virol (1974) 1.58
Mosquito cells infected with vesicular stomatitis virus yield unsialylated virions of low infectivity. J Virol (1975) 1.57
Differential inhibition of host protein synthesis in L cells infected with RNA - temperature-sensitive mutants of vesicular stomatitis virus. J Virol (1976) 1.55
Enveloped viruses as model membrane systems: microviscosity of vesicular stomatitis virus and host cell membranes. Biochemistry (1976) 1.54
Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity. J Virol (1982) 1.54
The efficacy of specimen radiography in evaluating the surgical margins of impalpable breast carcinoma. AJR Am J Roentgenol (1994) 1.54
Inhibition of RNA synthesis in mouse myeloma cells infected with vesicular stomatitis virus. J Virol (1978) 1.51
Safety, accuracy, and diagnostic yield of needle localization biopsy of the breast performed using local anesthesia. J Am Coll Surg (1994) 1.49
Modeling particle exposure in U.S. trucking terminals. Environ Sci Technol (2006) 1.49
Reconstitution into liposomes of the glycoprotein of vesicular stomatitis virus by detergent dialysis. J Biol Chem (1979) 1.48
Dose coefficients for the embryo and foetus following intakes of radionuclides by the mother. J Radiol Prot (2002) 1.47
Nucleus-targeting domain of the matrix protein (M1) of influenza virus. J Virol (1995) 1.46
The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol (1992) 1.45
Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun (1984) 1.45
Reversible inhibition of interferon synthesis by puromycin: evidence for an interferon-specific messenger RNA. Proc Natl Acad Sci U S A (1965) 1.44
RNA- temperature-sensitive mutants of vesicular stomatitis virus: L-protein thermosensitivity accounts for transcriptase restriction of group I mutants. J Virol (1976) 1.44
Use of UV irradiation to identify the genetic information of vesicular stomatitis virus responsible for shutting off cellular RNA synthesis. J Virol (1979) 1.44
2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol (2000) 1.43
Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab (2001) 1.42
Transcription inhibition and other properties of matrix proteins expressed by M genes cloned from measles viruses and diseased human brain tissue. J Virol (1994) 1.42
Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia (2006) 1.42
Deletions of fetal and adult muscle cDNA in Duchenne and Becker muscular dystrophy patients. EMBO J (1987) 1.40
The use of viscoelastic substances in the drainage of postoperative suprachoroidal hemorrhage. Ophthalmic Surg (1989) 1.40
Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun (1998) 1.39
Fungal virus capsids, cytoplasmic compartments for the replication of double-stranded RNA, formed as icosahedral shells of asymmetric Gag dimers. J Mol Biol (1994) 1.39
Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol (1999) 1.39
Membrane-binding domains and cytopathogenesis of the matrix protein of vesicular stomatitis virus. J Virol (1994) 1.39
Health effects of gasoline exposure. II. Mortality patterns of distribution workers in the United States. Environ Health Perspect (1993) 1.39
Pulmonary effects of exposures in silicon carbide manufacturing. Br J Ind Med (1984) 1.39
Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor bearing quadrant. Int J Radiat Oncol Biol Phys (1993) 1.38
Corneal traction suture in trabeculectomy. Ophthalmic Surg (1991) 1.37